全文获取类型
收费全文 | 23305篇 |
免费 | 1390篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 163篇 |
儿科学 | 747篇 |
妇产科学 | 767篇 |
基础医学 | 2936篇 |
口腔科学 | 336篇 |
临床医学 | 3699篇 |
内科学 | 3915篇 |
皮肤病学 | 213篇 |
神经病学 | 2423篇 |
特种医学 | 427篇 |
外科学 | 2072篇 |
综合类 | 266篇 |
一般理论 | 32篇 |
预防医学 | 3367篇 |
眼科学 | 336篇 |
药学 | 1369篇 |
中国医学 | 24篇 |
肿瘤学 | 1646篇 |
出版年
2024年 | 15篇 |
2023年 | 153篇 |
2022年 | 232篇 |
2021年 | 428篇 |
2020年 | 295篇 |
2019年 | 449篇 |
2018年 | 554篇 |
2017年 | 416篇 |
2016年 | 464篇 |
2015年 | 555篇 |
2014年 | 758篇 |
2013年 | 1149篇 |
2012年 | 1703篇 |
2011年 | 1846篇 |
2010年 | 963篇 |
2009年 | 869篇 |
2008年 | 1590篇 |
2007年 | 1715篇 |
2006年 | 1609篇 |
2005年 | 1582篇 |
2004年 | 1575篇 |
2003年 | 1442篇 |
2002年 | 1419篇 |
2001年 | 246篇 |
2000年 | 163篇 |
1999年 | 191篇 |
1998年 | 270篇 |
1997年 | 232篇 |
1996年 | 168篇 |
1995年 | 184篇 |
1994年 | 164篇 |
1993年 | 126篇 |
1992年 | 127篇 |
1991年 | 109篇 |
1990年 | 82篇 |
1989年 | 78篇 |
1988年 | 70篇 |
1987年 | 78篇 |
1986年 | 54篇 |
1985年 | 81篇 |
1984年 | 69篇 |
1983年 | 61篇 |
1982年 | 68篇 |
1981年 | 60篇 |
1980年 | 40篇 |
1979年 | 39篇 |
1978年 | 24篇 |
1977年 | 22篇 |
1976年 | 14篇 |
1974年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
3.
4.
5.
Aaron H. Burstein Pharm.D. William G. Reiss Pharm.D. Eric Kantor B.A. Gail D. Anderson Ph.D. 《Pharmacotherapy》1998,18(6):1271-1276
Study Objective . To characterize cytochrome P450 (CYP) 3A4 activity in premenopausal and postmenopausal women by evaluating the urinary 6-β-hydroxycortisokcortisol ratio. Design . Prospective study. Subjects . Thirteen premenopausal and 13 postmenopausal women who were healthy and not receiving drugs known to affect CYP3A4 activity. Interventions . Beginning on day 2 of menses, premenopausal women collected first morning urine samples every other day for a complete menstrual cycle. Postmenopausal women collected first morning urine every other day for 28 days. Measurements and Main Results . Mean weekly 6-β-hydroxycortisol:cortisol ratios did not differ during the phase (week) of the menstrual cycle. Daily ratios did not differ in postmenopausal women. No difference between premenopausal and postmenopausal women was found on comparing overall median ratios. Conclusion . Cytochrome P450 3A4 activity as measured by 6-β-hydroxy cortisol:cortisol ratio did not differ by week of menstrual cycle, suggesting no menstrual cycle-related changes. Menopause does not appear to be associated with differences in CYP3A4 activity, compared with premenopause. 相似文献
6.
7.
Castleman disease is a rare disorder characterized by lymphoid hyperplasia which rarely manifests in children. We present 2 cases which highlight both histologic variants of this disease, and provide suggestions regarding workup and treatment with the goal of making practitioners aware of Castleman disease in the differential diagnosis of a child presenting with vague symptoms. 相似文献
8.
Seymour Solomon Brian M Grosberg Deborah I Friedman Richard B Lipton 《Journal of neuro-ophthalmology》2007,27(3):243-4; author reply 244-5
9.
10.
Deborah P Jones Carlos A Camargo Frank E Speizer R Graham Barr 《The Journal of asthma》2007,44(4):291-295
The authors tested the hypothesis that short stature predicts adult-onset asthma independent of obesity among women in the Nurses' Health Study. Height, weight, and physician-diagnosed asthma were assessed with validated questionnaire items. Proportional hazard models adjusted separately for weight and body mass index. The rate of newly diagnosed asthma was 1.55 times greater in the shortest versus the tallest quintile after adjustment for weight (95% CI, 1.26-1.91). After adjustment for body mass index, the rate ratio was 1.16 (95% CI, 0.94-1.42). Short stature predicted adult-onset asthma in a large cohort of women, but this association was not independent of obesity. 相似文献